A novel CRIg-targeted complement inhibitor protects cells from complement damage

FASEB Journal

Volumn 28, Issue 11, 2014, Pages 4986-4999

  Qiao, Qian ^a,b   Teng, Xiaoyan ^a,b   Wang, Na ^a,b   Lu, Renquan ^a,b   Guo, Lin ^a,b   Zhang, Xin ^a,b   Du, Yiqun ^a,b   Wang, Wenjuan ^c   Chen, Suning ^c   Wu, Qian ^c   He, Guangsheng ^c   Wang, Yingwei ^d   Hu, Weiguo ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Factor H; Mesangioproliferative glomerulonephritis; Paroxysmal nocturnal hemoglobinuria

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR; COMPLEMENT RECEPTOR OF THE IMMUNOGLOBULIN; UNCLASSIFIED DRUG; CRIG PROTEIN, MOUSE; CRIG PROTEIN, RAT;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL DAMAGE; CELL PROTECTION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DISSOCIATION; ERYTHROCYTE; FEMALE; FLOW CYTOMETRY; HEMOLYSIS; HUMAN; HUMAN CELL; IC50; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MOUSE; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; RAT; RAT MODEL; TRANSIENT TRANSFECTION; ANIMAL; DISEASE MODEL; GLOMERULONEPHRITIS; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; COMPLEMENT C3B; COMPLEMENT FACTOR H; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT PATHWAY, ALTERNATIVE; DISEASE MODELS, ANIMAL; ERYTHROCYTES; GLOMERULONEPHRITIS; HEMOLYSIS; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, COMPLEMENT;

EID: 84912000350     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-258046     Document Type: Article

References (49)

1. Ricklin, D., and Lambris, J. D. (2007) Complement-targeted therapeutics. Nat. Biotechnol. 25, 1265-1275
2. Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J. D. (2010) Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785-797
3. Qu, H., Magotti, P., Ricklin, D., Wu, E. L., Kourtzelis, I., Wu, Y. Q., Kaznessis, Y. N., and Lambris, J. D. (2011) Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol. Immunol. 48, 481-489
4. Harboe, M., and Mollnes, T. E. (2008) The alternative complement pathway revisited. J. Cell. Mol. Med. 12, 1074-1084
5. Janssen, B. J., Christodoulidou, A., McCarthy, A., Lambris, J. D., and Gros, P. (2006) Structure of C3b reveals conformational changes that underlie complement activity. Nature 444, 213-216
6. Helmy, K. Y., Katschke K. J., Jr., Gorgani, N. N., Kljavin, N. M., Elliott, J. M., Diehl, L., Scales, S. J., Ghilardi, N., and van Lookeren Campagne, M. (2006) CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124, 915-927
7. Gordon, D. L., Kaufman, R. M., Blackmore, T. K., Kwong, J., and Lublin, D. M. (1995) Identification of complement regulatory domains in human factor H. J. Immunol. 155, 348-356
8. Sharma, A. K., and Pangburn, M. K. (1996) Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc. Natl. Acad. Sci. U.S.A. 93, 10996-11001
9. Wu, J., Wu, Y.-Q., Ricklin, D., Janssen, B. J., Lambris, J. D., and Gros, P. (2009) Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10, 728-733
10. Wiesmann, C., Katschke, K. J., Yin, J., Helmy, K. Y., Steffek, M., Fairbrother, W. J., McCallum, S. A., Embuscado, L., DeForge, L., Hass, P. E., and van Lookeren Campagne, M. (2006) Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature 444, 217-220
11. Miyata, T., Takeda, J., Iida, Y., Yamada, N., Inoue, N., Takahashi, M., Maeda, K., Kitani, T., and Kinoshita, T. (1993) The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science 259, 1318-1320
12. Parker, C. J. (1996) Molecular basis of paroxysmal nocturnal hemoglobinuria. Stem Cells 14, 396-411
13. Brodsky, R. A., Young, N. S., Antonioli, E., Risitano, A. M., Schrezenmeier, H., Schubert, J., Gaya, A., Coyle, L., de Castro, C., Fu, C. L., Maciejewski, J. P., Bessler, M., Kroon, H. A., Rother, R. P., and Hillmen, P. (2008) Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 111, 1840-1847
14. Fridkis-Hareli, M., Storek, M., Mazsaroff, I., Risitano, A. M., Lundberg, A. S., Horvath, C. J., and Holers, V. M. (2011) Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118, 4705-4713
15. Song, H., He, C., Knaak, C., Guthridge, J. M., Holers, V. M., and Tomlinson, S. (2003) Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J. Clin. Invest. 111, 1875-1885
16. Banda, N. K., Levitt, B., Glogowska, M. J., Thurman, J. M., Takahashi, K., Stahl, G. L., Tomlinson, S., Arend, W. P., and Holers, V. M. (2009) Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J. Immunol. 183, 5928-5937
17. Rohrer, B., Long, Q., Coughlin, B., Wilson, R. B., Huang, Y., Qiao, F., Tang, P. H., Kunchithapautham, K., Gilkeson, G. S., and Tomlinson, S. (2009) A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 50, 3056-3064
18. Risitano, A. M., Notaro, R., Pascariello, C., Sica, M., del Vecchio, L., Horvath, C. J., Fridkis-Hareli, M., Selleri, C., Lindorfer, M. A., and Taylor, R. P. (2012) The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 119, 6307-6316
19. Katschke, K. J., Helmy, K. Y., Steffek, M., Xi, H., Yin, J., Lee, W. P., Gribling, P., Barck, K. H., Carano, R. A., and Taylor, R. E. (2007) A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis. J. Exp. Med. 204, 1319-1325
20. Aricescu, A. R., Lu, W., and Jones, E. Y. (2006) A time-and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62, 1243-1250
21. Hu, W., Yu, Q., Hu, N., Byrd, D., Amet, T., Shikuma, C., Shiramizu, B., Halperin, J. A., and Qin, X. (2010) A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS. J. Immunol. 184, 359-368
22. Zhou, X., Hu, W., and Qin, X. (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13, 954-966
23. Liu, L., Qiu, W., Wang, H., Li, Y., Zhou, J., Xia, M., Shan, K., Pang, R., Zhou, Y., and Zhao, D. (2012) Sublytic C5b-9 complexes induce apoptosis of glomerular mesangial cells in rats with Thy-1 nephritis through role of interferon regulatory factor-1- dependent caspase 8 activation. J. Biol. Chem. 287, 16410-16423
24. Triantafilou, K., Hughes, T. R., Triantafilou, M., and Morgan, B. P. (2013) The complement membrane attack complex triggers intracellular Ca2+fluxes leading to NLRP3 inflammasome activation. J. Cell Sci. 126, 2903-2913
25. Ollert, M. W., Kadlec, J. V., David, K., Petrella, E. C., Bredehorst, R., and Vogel, C. W. (1994) Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J. Immunol. 153, 2213-2221
26. Parker, C., Omine, M., Richards, S., Nishimura, J., Bessler, M., Ware, R., Hillmen, P., Luzzatto, L., Young, N., Kinoshita, T., Rosse, W., and Socie, G. (2005) Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood 106, 3699-3709
27. Peters, D. K., Martin, A., Weinstein, A., Cameron, J. S., Barratt, T. M., Ogg, C. S., and Lachmann, P. J. (1972) Complement studies in membrano-proliferative glomerulonephritis. Clin. Exp. Immunol. 11, 311-320
28. Turnberg, D., and Cook, H. T. (2005) Complement and glomerulonephritis: new insights. Curr. Opin. Nephrol. Hypertens. 14, 223-228
29. Tanaka, T., Matsumoto, M., Inagi, R., Miyata, T., Kojima, I., Ohse, T., Fujita, T., and Nangaku, M. (2005) Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int. 68, 2714-2725
30. Brandt, J., Pippin, J., Schulze, M., Hansch, G. M., Alpers, C. E., Johnson, R. J., Gordon, K., and Couser, W. G. (1996) Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int. 49, 335-343
31. Longhurst, H., Carr, S., and Khair, K. (2007) C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin. Exp. Immunol. 147, 11-17
32. Weisman, H. F., Bartow, T., Leppo, M. K., Boyle, M. P., Marsh, H. C., Jr., Carson, G. R., Roux, K. H., Weisfeldt, M. L., and Fearon, D. T. (1990) Recombinant soluble CR1 suppressed complement activation, inflammation, and necrosis associated with reperfusion of ischemic myocardium. Trans. Assoc. Am. Physicians 103, 64-72
33. Li, J. S., Jaggers, J., and Anderson, P. A. (2006) The use of TP10, soluble complement receptor 1, in cardiopulmonary bypass. Expert. Rev. Cardiovasc. Ther. 4, 649-654
34. Koehl, J. (2006) Drug evaluation: the C5a receptor antagonist PMX-53. Curr. Opin. Mol. Therap. 8, 529
35. Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., and Bell, L. (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol. 25, 1256-1264
36. Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., and Evans, M. J. (1996) Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol. Immunol. 33, 1389-1401
37. Ricklin, D., and Lambris, J. D. (2008) Compstatin: a complement inhibitor on its way to clinical application. Adv. Exp. Med. Biol. 632, 273-292
38. Risitano, A. M., Ricklin, D., Huang, Y., Reis, E. S., Chen, H., Ricci, P., Lin, Z., Pascariello, C., Raia, M., Sica, M., Del Vecchio, L., Pane, F., Lupu, F., Notaro, R., Resuello, R. R., Deangelis, R. A., and Lambris, J. D. (2014) Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood 123, 2094-2101
39. Lindorfer, M. A., Pawluczkowycz, A. W., Peek, E. M., Hickman, K., Taylor, R. P., and Parker, C. J. (2010) A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 115, 2283-2291
40. Van der Schoot, C., Huizinga, T., Van't Veer-Korthof, E., Wijmans, R., Pinkster, J., and Von Dem Borne, A. (1990) Deficiency of glycosyl-phosphatidylinositol-linked membrane glycoproteins of leukocytes in paroxysmal nocturnal hemoglobinuria, description of a new diagnostic cytofluorometric assay. Blood 76, 1853-1859
41. Hebecker, M., Alba-Dominguez, M., Roumenina, L. T., Reuter, S., Hyvarinen, S., Dragon-Durey, M. A., Jokiranta, T. S., Sanchez- Corral, P., and Jozsi, M. (2013) An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J. Immunol. 191, 912-921
42. Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J. Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., Bracken, M. B., Ferris, F. L., Ott, J., Barnstable, C., and Hoh, J. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389
43. Zipfel, P. F., Lauer, N., and Skerka, C. (2010) The role of complement in AMD. Adv. Exp. Med. Biol. 703, 9-24
44. Noris, M., and Remuzzi, G. (2009) Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361, 1676-1687
45. Alegretti, A. P., Schneider, L., Piccoli, A. K., and Xavier, R. M. (2012) The role of complement regulatory proteins in peripheral blood cells of patients with systemic lupus erythematosus: review. Cell. Immunol. 277, 1-7
46. Ruiz-Arguelles, A., and Llorente, L. (2007) The role of complement regulatory proteins (CD55 and CD59) in the pathogenesis of autoimmune hemocytopenias. Autoimmun. Rev. 6, 155-161
47. Song, W. C. (2006) Complement regulatory proteins and autoimmunity. Autoimmunity 39, 403-410
48. Barros, M. M., Yamamoto, M., Figueiredo, M. S., Cancado, R., Kimura, E. Y., Langhi, D. M., Jr., Chiattone, C. S., and Bordin, J. O. (2009) Expression levels of CD47, CD35, CD55, and CD59 on red blood cells and signal-regulatory protein-alpha,beta on monocytes from patients with warm autoimmune hemolytic anemia. Transfusion 49, 154-160
49. Keating, G. M. (2013) Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs 73, 2053-2066